Diasorin

Candida auris is a serious, multidrug-resistant fungal pathogen that spreads easily in healthcare settings. It can lead to deadly outbreaks, especially in hospitals and long-term care facilities. Why is C. auris such a threat? • It’s resistant to multiple antifungal treatments • It persists on surfaces for weeks • It’s often misidentified with standard lab methods Watch the CDC's quick C. auris video to learn more: https://hubs.li/Q03PM-zx0 When every minute counts, Simplexa® C. auris Direct helps labs act fast, helping protect patients and prevent the spread. https://hubs.li/Q03PMYbX0 #InfectionPreventionWeek #Candidaauris #PatientSafety #InfectionControl #Diagnostics

A recent study in the Journal of Clinical Microbiology, conducted by Johns Hopkins Health System, offers a compelling case for moving from traditional fixed syndromic panels to flexible syndromic testing using the LIAISON PLEX® RSP Flex Assay. Key Findings: • Customizable Testing –Select only the targets you need, pay only for what you report, and release additional results as needed—no retesting or additional processing required. • Operational Efficiency – The study estimated over 92 staff hours could be saved per respiratory season by avoiding repeat testing and second swabs. • Diagnostic Stewardship – Alignment of testing with clinical need and local trends can reduce waste and improve care. Read a summary of the study on our blog: https://hubs.li/Q03LghBh0 #JohnsHopkins #DiagnosticStewardship #RespiratoryTesting #Respiratory #Diagnostics #ClinicalMicrobiology #Diasorin #LIAISONPLEX #LabEfficiency

Despite its prevalence, congenital cytomegalovirus (cCMV) remains underdiagnosed due to the lack of universal newborn screening. In our upcoming Labroots webinar, Dr. Megan Pesch will share the recent advances in cCMV testing platforms and discuss how early identification can support timely intervention and better developmental outcomes.  Don’t miss this opportunity to learn more about cCMV screening advancements and public policy initiatives. Register now for free and earn CE credits. https://hubs.li/Q03PkHkL0 #CongenitalCMV #InfectiousDisease #newbornheatlh #HealthcareInnovation #PublicHealthPolicy

In Episode 4, host Angelo Rago speaks with Dr. Margie Morgan, Director of Clinical Microbiology at Cedars-Sinai Medical Center, about the evolving role of diagnostic stewardship in today’s clinical labs. Dr. Morgan shares how her team uses innovative strategies—like soft stops, hard stops, and test ordering design—to guide physicians toward the most appropriate diagnostic tests. The goal? Better outcomes, lower costs, and smarter use of lab resources. “More is better” is no longer the rule. Targeted testing with reflex options is the future. Now streaming wherever you get your podcasts: https://hubs.li/Q03P5K1-0 #BeyondTheResult #DiagnosticStewardship #ClinicalMicrobiology #HealthcareInnovation #LabLeadership Stephanie Ibbotson Michelle Tabb

Diasorin is committed to supporting labs in tackling sepsis and antimicrobial resistance through innovative diagnostic solutions that enable timely interventions safeguarding lives and preserving treatment efficacy. With comprehensive coverage of bacterial and fungal pathogens and important variants of resistance genes coverage, LIAISON PLEX® BSI offer 3 assays—60 targets in total—to choose from based on workflow, patient and healthcare needs. Through smarter diagnostic solutions, the LIAISON PLEX® BSI assays empower healthcare providers with rapid, precise insights to advance antimicrobial stewardship initiatives and optimize patient management outcomes. Discover our LIAISON PLEX® Bloodstream Infection portfolio now https://hubs.li/Q03MKTv60 #Diagnostics #SepsisAwareness #AMR #diagnosticstewardship #HealthcareInnovation #antimicrobialstewardship

Join us at IDWeek 2025 in Atlanta and visit Booth #1427 to explore the newly launched LIAISON PLEX® Bloodstream Infection (BSI) portfolio. Featuring three FDA-cleared multiplex molecular assays, this portfolio delivers smart, clinically relevant solutions for detecting 48 bacterial and fungal species and 12 key resistance genes. Don’t miss the session on Tuesday, October 21 at 10:15 a.m. with Dr. Melissa Miller, PhD, D(ABMM), FAAM, FIDSA: LIAISON PLEX® Bloodstream Infection Assays: Introducing Smarter and Comprehensive Diagnostic Solutions See how this platform enhances diagnostic precision, supports antimicrobial stewardship, and improves patient outcomes. Learn more about the session and register for IDWeek 2025: https://hubs.li/Q03LGKJZ0 #IDWeek2025 #BloodstreamInfections #ClinicalMicrobiology #InfectiousDiseases #HealthcareTechnology

When labs evaluate new molecular tests, clinical performance is only part of the equation. Reimbursement, provider adoption, and operational fit are just as critical. That’s where Market Access comes in. Our Market Access team helps labs navigate coding, coverage, and reimbursement challenges from day one, because a great test only matters if you can afford to run it. Explore how we help your lab align clinical and financial goals. https://hubs.li/Q03Mz8-30 #MarketAccess #DiagnosticInnovation #HealthcareEquity #PrecisionMedicine #HealthTech

In today's dynamic respiratory testing landscape, choosing the right tests for your patients can often feel like piecing together a complex puzzle. Diasorin's comprehensive syndromic and targeted portfolio supports respiratory testing algorithms that meet today's diagnostic stewardship needs. Explore our free respiratory eBook today to learn more and get ahead of the changing respiratory testing landscape. https://hubs.li/Q03MT1460 #DiagnosticStewardship #RespiratoryHealth #FlexibleTesting #eBook

Despite causing birth defects more frequently than any other infectious disease in the US, congenital cytomegalovirus (cCMV) is not required to be included in most newborn screening panels and often goes undetected. Join Dr. Megan Pesch, developmental and behavioral pediatrician and cCMV researcher, for a webinar on Labroots to explore the latest cCMV screening updates and public policy news. Sign up for free to learn about emerging testing technologies, evolving state regulations, and the critical role of early detection in improving long-term health outcomes. Register now to learn about cCMV screening and earn CE credits. https://hubs.li/Q03MzfG_0 #cCMV #NewbornScreening #PediatricHealth #EarlyIntervention #MedicalResearch